Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Renal enlargement in polycystic kidney disease (PKD) is caused by the proliferation of mural epithelial cells and transepithelial fluid secretion into the cavities of innumerable cysts. Arginine vasopressin (AVP) stimulates the proliferation of human PKD cells in vitro via cAMP-dependent activation of the B-Raf/MEK (MAPK/ERK kinase/extracellular signal-regulated kinase (ERK) pathway. ERK activity is elevated in cells that line the cysts in animals with PKD, and AVP receptor antagonists reduce ERK activity and halt disease progression. For suppression of the effect of AVP physiologically, water intake was increased in PCK rats, a model of PKD, and the effect on renal morphology, cellular mechanism, and function was determined. The addition of 5% glucose in the drinking water increased fluid intake approximately 3.5-fold compared with rats that received tap water. In PCK rats, increased water intake for 10 wk reduced urinary AVP excretion (68.3%), and urine osmolality fell below 290 mOsmol/kg. High water intake was associated with reduced renal expression of AVP V2 receptors (41.0%), B-Raf (15.4%), phosphorylated ERK (38.1%), and proliferating cell nuclear antigen-positive renal cells (61.7%). High water intake reduced the kidney/body weight ratio 28.0% and improved renal function. Taken together, these data demonstrate that water intake that is sufficient to cause persistent water diuresis suppresses B-Raf/MEK/ERK activity and decreases cyst and renal volumes in PCK rats. It is suggested that limiting serum AVP levels by increased water intake may be beneficial to some patients with PKD.

[1]  V. Torres Water for ADPKD? Probably, yes. , 2006, Journal of the American Society of Nephrology : JASN.

[2]  G. Germino,et al.  Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  D. Wallace,et al.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. , 2005, Journal of the American Society of Nephrology : JASN.

[4]  C. Edelstein What is the Role of Tubular Epithelial Cell Apoptosis in Polycystic Kidney Disease (PKD)? , 2005, Cell cycle.

[5]  H. Kurahashi,et al.  Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. , 2005, Journal of the American Society of Nephrology.

[6]  V. Torres,et al.  Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  W. Bennett V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  James P Calvet,et al.  Calcium Restriction Allows cAMP Activation of the B-Raf/ERK Pathway, Switching Cells to a cAMP-dependent Growth-stimulated Phenotype* , 2004, Journal of Biological Chemistry.

[9]  V. Torres Therapies to Slow Polycystic Kidney Disease , 2004, Nephron Experimental Nephrology.

[10]  D. Wallace,et al.  Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. , 2004, Kidney international.

[11]  S. Somlo,et al.  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease , 2004, Nature Medicine.

[12]  S. Somlo,et al.  Histopathological analysis of renal cystic epithelia in the Pkd2WS25/- mouse model of ADPKD. , 2003, American journal of physiology. Renal physiology.

[13]  Vincent H Gattone,et al.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.

[14]  J. Pelling,et al.  Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. , 2003, Kidney international.

[15]  A. Levey,et al.  High urine volume and low urine osmolality are risk factors for faster progression of renal disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  R. Maser,et al.  Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. , 2003, Kidney international.

[17]  P. Harris Molecular basis of polycystic kidney disease: PKD1, PKD2 and PKHD1 , 2002, Current opinion in nephrology and hypertension.

[18]  N. Gretz,et al.  Molecular basis of autosomal-dominant polycystic kidney disease , 2002, Cellular and Molecular Life Sciences CMLS.

[19]  G. Delitala,et al.  Decreased nocturnal urinary antidiuretic hormone excretion in enuresis is increased by imipramine , 2001, BJU international.

[20]  K. Tomita,et al.  Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. , 2001, Cardiovascular research.

[21]  W. Guggino,et al.  cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. , 2000, Journal of the American Society of Nephrology : JASN.

[22]  L P Sullivan,et al.  cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. , 2000, Kidney international.

[23]  J. Sands,et al.  Urea transport processes are induced in rat IMCD subsegments when urine concentrating ability is reduced. , 1999, American journal of physiology. Renal physiology.

[24]  S. Nagao,et al.  Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  P. Wilson,et al.  Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease. , 1996, The American journal of physiology.

[26]  Patricia A. Gabow,et al.  PKD2, a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein , 1996, Science.

[27]  R. Perrone,et al.  Water channel expression in human ADPKD kidneys. , 1995, The American journal of physiology.

[28]  I. Ramirez Why do sugars taste good? , 1990, Neuroscience & Biobehavioral Reviews.

[29]  Ann M. Johnson,et al.  The clinical utility of renal concentrating capacity in polycystic kidney disease. , 1989, Kidney international.

[30]  Verani Rr,et al.  Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. , 1988 .

[31]  A. Bakkaloğlu,et al.  Mutation analysis of the entire PKD1 gene: genetic and diagnostic implications. , 2001, American journal of human genetics.

[32]  V. Torres,et al.  The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. , 2001, Kidney international.

[33]  H. Takahashi,et al.  Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. , 2000, Experimental animals.

[34]  R. Maser,et al.  Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. , 1999, Developmental genetics.

[35]  F. Silva,et al.  Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.